0001127602-21-014507.txt : 20210427
0001127602-21-014507.hdr.sgml : 20210427
20210427161517
ACCESSION NUMBER: 0001127602-21-014507
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210423
FILED AS OF DATE: 20210427
DATE AS OF CHANGE: 20210427
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoge Stephen
CENTRAL INDEX KEY: 0001760669
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 21859082
MAIL ADDRESS:
STREET 1: C/O MODERNA, INC.
STREET 2: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-04-23
0001682852
Moderna, Inc.
MRNA
0001760669
Hoge Stephen
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
President
Common Stock
2021-04-23
4
M
0
5000
10.90
A
1614597
D
Common Stock
2021-04-23
4
M
0
10000
.99
A
1624597
D
Common Stock
2021-04-23
4
S
0
561
169.18
D
1624036
D
Common Stock
2021-04-23
4
S
0
5100
170.18
D
1618936
D
Common Stock
2021-04-23
4
S
0
1000
171.77
D
1617936
D
Common Stock
2021-04-23
4
S
0
2200
172.81
D
1615736
D
Common Stock
2021-04-23
4
S
0
4639
173.81
D
1611097
D
Common Stock
2021-04-23
4
S
0
1400
174.46
D
1609697
D
Common Stock
2021-04-23
4
S
0
100
175.34
D
1609597
D
Common Stock
2021-04-26
4
M
0
5000
10.90
A
1614597
D
Common Stock
2021-04-26
4
S
0
5000
171.77
D
1609597
D
Common Stock
4116
I
By Valhalla, LLC
Common Stock
151933
I
By Trust
Stock Option (Right to Buy)
10.90
2021-04-23
4
M
0
5000
0
D
2026-02-23
Common Stock
5000
331972
D
Stock Option (Right to Buy)
.99
2021-04-23
4
M
0
10000
0
D
2023-08-19
Common Stock
10000
517431
D
Stock Option (Right to Buy)
10.90
2021-04-26
4
M
0
5000
0
D
2026-02-23
Common Stock
5000
326972
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.69 to $169.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.17 to $170.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.21 to $172.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.22 to $173.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.26 to $174.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.28 to $174.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter.
This option is fully vested and exercisable.
/s/ Brian Sandstrom, as Attorney-in-Fact
2021-04-27